SYS6090 + bevacizumab + FOLFOXIRI

SYS6090 + bevacizumab + FOLFOXIRI is an investigational combination therapy regimen being developed by CSPC Megalith Biopharmaceutical for the treatment of advanced or metastatic colorectal cancer. The regimen combines SYS6090, a recombinant humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, with bevacizumab, an anti-angiogenic monoclonal antibody targeting vascular endothelial growth factor (VEGF), and the FOLFOXIRI chemotherapy backbone (comprising fluorouracil, leucovorin, oxaliplatin, and irinotecan). This intensive combination is primarily being evaluated in patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) colorectal cancer, a population that has historically shown limited response to single-agent immune checkpoint inhibitors. The rationale for this approach is to utilize the cytotoxic and anti-angiogenic effects of chemotherapy and bevacizumab to potentially sensitize the tumor microenvironment to PD-1 blockade, thereby improving therapeutic efficacy.

Other names

SYS6090 + bevacizumab + fluorouracil + leucovorin + oxaliplatin + irinotecan